EGFR and esophageal squamous cell carcinoma: Moreover, genomically silencing AXL could not resensitize these resistance cells to EGFR inhibition or block downstream pathways (Supplementary Fig. 7a–e), suggesting that AXL may not serve as an effective target to sensitize mesenchymal EGFR-amplified ESCC to EGFR inhibition.